| Name | Scancell Holdings |
|---|---|
| Epic | SCLP |
| Isin | GB00B63D3314 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 13.75p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £127.60 | Debt ratio | n/a |
| Shares in issue | 927.98 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -120.59 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.5 | 52-week high / low | 8.92p / 19.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Scancell Holdings |
|---|---|
| Address | Bellhouse Building, Sanders Road, Oxford Science Park, Oxford, United Kingdom, OX4 4GD |
| Telephone | |
| Website | http://www.scancell.co.uk/ |
| Director | Position |
|---|---|
| Professor Lindy Durrant | CEO |
| Mr Sath Nirmalananthan | CFO |
| Ms Ursula Ney | Non-Executive Director |
| Mr Martin Diggle | Non-Executive Director |
| Ms Susan Clement Davies | Deputy Chairman |
| Mr Jean-Michel Cosséry | Non-Executive Chairman |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/04/23 | 30/04/22 | 30/04/21 |
| Intangible asssets and goodwill | 3.42 | 3.42 | 3.42 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 5.66 | 6.16 | 4.39 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.54 | 0.65 | 0.97 |
| Cash and equivalents | 19.92 | 28.73 | 41.11 |
| Other current assets and asset held for resale | 4.15 | 2.99 | 2.59 |
| Total of all assets | 30.27 | 38.52 | 49.06 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 3.28 | 2.45 | 2.29 |
| Long term liabilities | 33.23 | 31.26 | 27.28 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 36.5 | 33.71 | 29.57 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | -6.23 | 4.81 | 19.48 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.82 | 0.81 | 0.81 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -74.36 | -62.42 | -47.05 |
| Share premium account | 65.18 | 65.02 | 65.02 |
| Total equity | -6.23 | 4.81 | 19.48 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -11.92 | -13.3 | -8.83 |
| Pre-tax profit | -14.3 | -6.27 | -16.8 |